Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
Patients with hematologic malignancies
At least 18 years old
Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)
Male and females with new diagnosis/transformation/reactivation of hematologic malignancies
Cohort
Prospective
Not listed
To assess 365 days mortality of OHI+ and OHI- patients
The investigators will use Kaplan-Meier curves to compare survival between OHI+ and OHI- patients
To determine the incidence of OHI+ patients in our cohort
The investigators will assess the incidence of OHI+ within our cohort (OHI+/total patients enrolled)
Click on the lead sponsor to view all of their trials.
Meir Medical Center
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Collaborator
Rabin Medical Center
Collaborator
Sheba Medical Center
Collaborator
Schneider Children's Medical Center, Israel
Collaborator
